PharmaMar Seeks EMA Approval for New Lung Cancer Treatment

Pharma Mar SA ( (ES:PHM) ) just unveiled an update.

PharmaMar has submitted a marketing authorization application to the European Medicines Agency for Zepzelca® in combination with atezolizumab for first-line maintenance treatment in adult patients with advanced-stage small cell lung cancer. This application is based on significant results from the Phase 3 IMforte trial, highlighting the potential impact on PharmaMar’s operations and its positioning in the oncology market.

The most recent analyst rating on (ES:PHM) stock is a Buy with a EUR108.00 price target. To see the full list of analyst forecasts on Pharma Mar SA stock, see the ES:PHM Stock Forecast page.

More about Pharma Mar SA

PharmaMar is a biopharmaceutical company focused on developing new oncology treatments, aiming to improve patient health with innovative medicines. The company specializes in marine-derived drugs and has a strong presence in Europe, the United States, and Australia, with a robust R&D program in oncology.

Average Trading Volume: 59,329

Technical Sentiment Signal: Buy

Current Market Cap: €1.45B

Find detailed analytics on PHM stock on TipRanks’ Stock Analysis page.